Kiniksa Pharmaceuticals International (KNSA) Short-term Investments (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Short-term Investments came in at $350.3 million in Q2 2026, up 202.61% YoY from $115.7 million in Q2 2025, and up 25.93% on a QoQ basis from $278.1 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Short-term Investments (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Short-term Investments data on file, last reported at $350.3 million in Q2 2026.
- Quarterly Short-term Investments rose 202.61% year-over-year to $350.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $350.3 million (up 202.61% YoY) and the FY2025 annual result came in at $248.5 million, up 313.81% from the prior year.
- Short-term Investments rose to $350.3 million in Q2 2026, from $278.1 million in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $350.3 million in Q2 2026 to a low of $60.0 million in Q4 2024.
- A 5-year average of $141.5 million and a median of $113.5 million in 2025 frame the typical range for Short-term Investments.
- Annual changes were most pronounced in 2024 — Short-term Investments plunged 38.99% — and 2025, when it soared 313.81%.
- Tracing KNSA's Short-term Investments over 5 years: stood at $67.9 million in 2022, then surged by 44.96% to $98.4 million in 2023, then plunged by 38.99% to $60.0 million in 2024, then soared by 313.81% to $248.5 million in 2025, then soared by 40.96% to $350.3 million in 2026.
- The last three Short-term Investments figures came in at $350.3 million (Q2 2026), $278.1 million (Q1 2026), and $248.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Kiniksa Pharmaceuticals International | 6.04 Bn | 5.52 Bn | 220.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 350.25 Mn |
| Mar 31, 2026 | 278.14 Mn |
| Dec 31, 2025 | 248.48 Mn |
| Sep 30, 2025 | 177.24 Mn |
| Jun 30, 2025 | 115.75 Mn |
| Mar 31, 2025 | 111.21 Mn |
| Dec 31, 2024 | 60.05 Mn |
| Sep 30, 2024 | 126.40 Mn |
| Jun 30, 2024 | 119.49 Mn |
| Mar 31, 2024 | 72.47 Mn |
| Dec 31, 2023 | 98.42 Mn |
| Sep 30, 2023 | 83.26 Mn |
| Jun 30, 2023 | 72.43 Mn |
| Dec 31, 2022 | 67.89 Mn |
| Dec 31, 2021 | 59.73 Mn |
| Sep 30, 2021 | 10.00 Mn |
| Jun 30, 2021 | 57.91 Mn |
| Mar 31, 2021 | 144.17 Mn |
| Dec 31, 2020 | 209.44 Mn |
| Sep 30, 2020 | 278.52 Mn |